<DOC>
	<DOCNO>NCT01813513</DOCNO>
	<brief_summary>The purpose 3-part study evaluate potential impact simeprevir food pharmacokinetics ( PK ) IDX719 healthy participant . Part 1 evaluate potential PK interaction IDX719 simeprevir . Part 2 evaluate effect food PK IDX719 combination simeprevir . Part 3 evaluate impact high- versus low-fat meal PK IDX719 .</brief_summary>
	<brief_title>Study Evaluate Drug-Drug Interaction Between IDX719 Simeprevir Healthy Participants ( MK-1894-004 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Has clinically significant abnormality medical history , physical examination , 12lead electrocardiogram ( ECG ) Agrees use double method birth control ( one must barrier ) Screening least 90 day last dose study drug Agrees avoid nicotinecontaining product 3 month prior Screening duration study Is positive hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibody , antihuman immunodeficiency virus ( HIV ) antibodies Is pregnant breastfeeding Has previously receive either IDX719 simeprevir Has participate another clinical drug study within 30 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>antiviral drug</keyword>
	<keyword>liver</keyword>
</DOC>